0

Close
 
Upcoming Allied Market Research
2023
Chronic Lymphocytic Leukemia Therapeutics Market

Chronic Lymphocytic Leukemia Therapeutics Market

by Drug Type (Chemotherapy Drugs, Targeted Therapy, Others) and by Route of Administration (Oral Drugs, Intravenous Drugs, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A01162
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Chronic Lymphocytic Leukemia Therapeutics Market

Request Now !

Chronic Lymphocytic Leukemia (CLL) is a type of hematological malignancy marked by excessive proliferation of abnormal white blood cells. CLL predominantly affects the B-cell lymphocytes which are involved in the production of antibodies to fight against infections and foreign antigens. Rising incidence of CLL coupled with a high rate of mortality, demonstrates the unmet market need for better therapeutics. According to the American Cancer Society (ACS) estimate, more than 14000 new cases and more than 4,500 deaths are expected in the year 2015. CLL is more common among the aging population, with a higher frequency in the people aged 70 or above.
Family history of blood disorders and excessive exposure to harmful chemicals are the two important drivers for CLL treatment market. Higher incidences of leukemia coupled with improved diagnosis for CLL, growing disease awareness and rising incidences of comorbidities, especially among elders are other factors significant in determining the market growth. Furthermore, breakthrough therapy designation by FDA and discovery of some pipeline drugs would further accelerate the market growth. However, high cost of treatment, is likely to curtail the market growth.

The global Chronic Lymphocytic Leukemia Therapeutics market is segmented on the basis of drug type, route of administration and geography. On the basis of drug type, the market is segmented into Chemotherapy, Targeted Therapies and Others. The Targeted Therapy market is further segmented into approved drugs and pipeline drugs. According to route of administration, the market is segmented into Oral drugs, Intravenous drugs and others. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific and LAMEA.

Co-development and collaboration agreements are some of the key strategies adopted by leading market players. For instance, GlaxoSmithKline plc and Genmab A/S, have entered into co-development and collaboration agreement for drug Arzerra (ofatumumab), used in the treatment of relapsed CLL. Arzerra is a monoclonal antibody which targets CD20 molecule on the surface of CLL cells. Recently, Venetoclax, an investigational drug for the treatment of relapse or refractory CLL, has been granted Breakthrough Therapy Designation by US FDA. The drug is being developed by AbbVie in collaboration with Genentech and Roche. The companies profiled in the report include, GlaxoSmithKline Plc, Biogen Idec, Genentech Inc., F. Hoffmann-La Roche AG, Genzyme Corporation, Teva Pharmaceutical Industries Ltd., Celgene Corporation, Genmab A/S and AstraZeneca plc.

KEY MARKET BENEFITS:

  • Comprehensive analysis of factors that drive and restrict the growth of the global chronic lymphocytic leukemia therapeutics market is provided
  • The report provides a comprehensive analysis of the current market and estimations which would enable the stakeholders to capitalize on prevailing market opportunities
  • An in-depth analysis of key segments of the market demonstrate the types of drugs along with routes of administration in the CLL therapeutics market
  • An in-depth analysis of key segments of the market demonstrates the types of drugs and routes of administration that are currently being used along with the variants that would gain prominence in future
  • SWOT analysis enables to study the internal environment of the leading companies for strategy formulation
  • Region-wise Chronic Lymphocytic Leukemia Therapeutics market scenario is comprehensively analyzed in the report

 Chronic Lymphocytic Leukemia Therapeutics Market Report Highlights

Aspects Details
By Drug Type
  • Chemotherapy Drugs
  • Targeted Therapy
    • Approved Drugs
    • Pipeline Drugs
  • Others
By Route of Administration
  • Oral Drugs
  • Intravenous Drugs
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, UAE, Rest of LAMEA)
Key Market Players Genzyme Corporation, Biogen Idec, Celgene Corporation, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, AstraZeneca plc., Teva Pharmaceutical Industries Ltd., Genentech Inc., Genmab A/S
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Drug Type

    • 4.2. Chemotherapy Drugs

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Targeted Therapy

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

      • 4.3.4. Approved Drugs

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Pipeline Drugs

        • 4.3.4.1. Market Size and Forecast

    • 4.4. Others

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Route Of Administration

    • 5.2. Oral Drugs

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Intravenous Drugs

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Others

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Drug Type

      • 6.2.3. Market Size and Forecast, By Route Of Administration

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.2.5.1. Market Size and Forecast, By Drug Type
        • 6.2.5.2. Market Size and Forecast, By Route Of Administration

      • 6.2.6. Canada Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.2.6.1. Market Size and Forecast, By Drug Type
        • 6.2.6.2. Market Size and Forecast, By Route Of Administration

      • 6.2.7. Mexico Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.2.7.1. Market Size and Forecast, By Drug Type
        • 6.2.7.2. Market Size and Forecast, By Route Of Administration

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Drug Type

      • 6.3.3. Market Size and Forecast, By Route Of Administration

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.3.5.1. Market Size and Forecast, By Drug Type
        • 6.3.5.2. Market Size and Forecast, By Route Of Administration

      • 6.3.6. Germany Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.3.6.1. Market Size and Forecast, By Drug Type
        • 6.3.6.2. Market Size and Forecast, By Route Of Administration

      • 6.3.7. Italy Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.3.7.1. Market Size and Forecast, By Drug Type
        • 6.3.7.2. Market Size and Forecast, By Route Of Administration

      • 6.3.8. Spain Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.3.8.1. Market Size and Forecast, By Drug Type
        • 6.3.8.2. Market Size and Forecast, By Route Of Administration

      • 6.3.9. UK Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.3.9.1. Market Size and Forecast, By Drug Type
        • 6.3.9.2. Market Size and Forecast, By Route Of Administration

      • 6.3.10. Russia Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.3.10.1. Market Size and Forecast, By Drug Type
        • 6.3.10.2. Market Size and Forecast, By Route Of Administration

      • 6.3.11. Rest Of Europe Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.3.11.1. Market Size and Forecast, By Drug Type
        • 6.3.11.2. Market Size and Forecast, By Route Of Administration

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Drug Type

      • 6.4.3. Market Size and Forecast, By Route Of Administration

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.4.5.1. Market Size and Forecast, By Drug Type
        • 6.4.5.2. Market Size and Forecast, By Route Of Administration

      • 6.4.6. Japan Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.4.6.1. Market Size and Forecast, By Drug Type
        • 6.4.6.2. Market Size and Forecast, By Route Of Administration

      • 6.4.7. India Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.4.7.1. Market Size and Forecast, By Drug Type
        • 6.4.7.2. Market Size and Forecast, By Route Of Administration

      • 6.4.8. South Korea Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.4.8.1. Market Size and Forecast, By Drug Type
        • 6.4.8.2. Market Size and Forecast, By Route Of Administration

      • 6.4.9. Australia Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.4.9.1. Market Size and Forecast, By Drug Type
        • 6.4.9.2. Market Size and Forecast, By Route Of Administration

      • 6.4.10. Thailand Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.4.10.1. Market Size and Forecast, By Drug Type
        • 6.4.10.2. Market Size and Forecast, By Route Of Administration

      • 6.4.11. Malaysia Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.4.11.1. Market Size and Forecast, By Drug Type
        • 6.4.11.2. Market Size and Forecast, By Route Of Administration

      • 6.4.12. Indonesia Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.4.12.1. Market Size and Forecast, By Drug Type
        • 6.4.12.2. Market Size and Forecast, By Route Of Administration

      • 6.4.13. Rest of Asia Pacific Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.4.13.1. Market Size and Forecast, By Drug Type
        • 6.4.13.2. Market Size and Forecast, By Route Of Administration

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Drug Type

      • 6.5.3. Market Size and Forecast, By Route Of Administration

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.5.5.1. Market Size and Forecast, By Drug Type
        • 6.5.5.2. Market Size and Forecast, By Route Of Administration

      • 6.5.6. South Africa Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.5.6.1. Market Size and Forecast, By Drug Type
        • 6.5.6.2. Market Size and Forecast, By Route Of Administration

      • 6.5.7. Saudi Arabia Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.5.7.1. Market Size and Forecast, By Drug Type
        • 6.5.7.2. Market Size and Forecast, By Route Of Administration

      • 6.5.8. UAE Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.5.8.1. Market Size and Forecast, By Drug Type
        • 6.5.8.2. Market Size and Forecast, By Route Of Administration

      • 6.5.9. Argentina Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.5.9.1. Market Size and Forecast, By Drug Type
        • 6.5.9.2. Market Size and Forecast, By Route Of Administration

      • 6.5.10. Rest of LAMEA Chronic Lymphocytic Leukemia Therapeutics Market

        • 6.5.10.1. Market Size and Forecast, By Drug Type
        • 6.5.10.2. Market Size and Forecast, By Route Of Administration

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. GlaxoSmithKline Plc

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Biogen Idec

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Genentech Inc.

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. F. Hoffmann-La Roche AG

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Genzyme Corporation

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Teva Pharmaceutical Industries Ltd.

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Celgene Corporation

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Genmab A/S

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. AstraZeneca Plc.

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET FOR CHEMOTHERAPY DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET FOR TARGETED THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET FOR ORAL DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET FOR INTRAVENOUS DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. NORTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 13. U.S. CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 14. U.S. CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 15. CANADA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 16. CANADA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 17. MEXICO CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 18. MEXICO CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 19. EUROPE CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 22. FRANCE CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 23. FRANCE CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 24. GERMANY CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 25. GERMANY CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 26. ITALY CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 27. ITALY CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 28. SPAIN CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 29. SPAIN CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 30. UK CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 31. UK CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 32. RUSSIA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 33. RUSSIA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 34. REST OF EUROPE CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 35. REST OF EUROPE CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 37. ASIA-PACIFIC CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 38. ASIA-PACIFIC CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 39. CHINA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 40. CHINA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 41. JAPAN CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 42. JAPAN CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 43. INDIA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 44. INDIA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 45. SOUTH KOREA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 46. SOUTH KOREA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 47. AUSTRALIA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 48. AUSTRALIA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 49. THAILAND CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 50. THAILAND CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 51. MALAYSIA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 52. MALAYSIA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 53. INDONESIA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 54. INDONESIA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 57. LAMEA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 58. LAMEA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 59. LAMEA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 60. BRAZIL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 61. BRAZIL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 62. SOUTH AFRICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 63. SOUTH AFRICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 64. SAUDI ARABIA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 65. SAUDI ARABIA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 66. UAE CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 67. UAE CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 68. ARGENTINA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 69. ARGENTINA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 70. REST OF LAMEA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 71. REST OF LAMEA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 72. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 73. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 74. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 75. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 76. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 77. BIOGEN IDEC: KEY EXECUTIVES
  • TABLE 78. BIOGEN IDEC: COMPANY SNAPSHOT
  • TABLE 79. BIOGEN IDEC: OPERATING SEGMENTS
  • TABLE 80. BIOGEN IDEC: PRODUCT PORTFOLIO
  • TABLE 81. BIOGEN IDEC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 82. GENENTECH INC.: KEY EXECUTIVES
  • TABLE 83. GENENTECH INC.: COMPANY SNAPSHOT
  • TABLE 84. GENENTECH INC.: OPERATING SEGMENTS
  • TABLE 85. GENENTECH INC.: PRODUCT PORTFOLIO
  • TABLE 86. GENENTECH INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 87. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
  • TABLE 88. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
  • TABLE 89. F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS
  • TABLE 90. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
  • TABLE 91. F. HOFFMANN-LA ROCHE AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 92. GENZYME CORPORATION: KEY EXECUTIVES
  • TABLE 93. GENZYME CORPORATION: COMPANY SNAPSHOT
  • TABLE 94. GENZYME CORPORATION: OPERATING SEGMENTS
  • TABLE 95. GENZYME CORPORATION: PRODUCT PORTFOLIO
  • TABLE 96. GENZYME CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 97. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 98. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 99. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 100. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 101. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 102. CELGENE CORPORATION: KEY EXECUTIVES
  • TABLE 103. CELGENE CORPORATION: COMPANY SNAPSHOT
  • TABLE 104. CELGENE CORPORATION: OPERATING SEGMENTS
  • TABLE 105. CELGENE CORPORATION: PRODUCT PORTFOLIO
  • TABLE 106. CELGENE CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 107. GENMAB A/S: KEY EXECUTIVES
  • TABLE 108. GENMAB A/S: COMPANY SNAPSHOT
  • TABLE 109. GENMAB A/S: OPERATING SEGMENTS
  • TABLE 110. GENMAB A/S: PRODUCT PORTFOLIO
  • TABLE 111. GENMAB A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. ASTRAZENECA PLC.: KEY EXECUTIVES
  • TABLE 113. ASTRAZENECA PLC.: COMPANY SNAPSHOT
  • TABLE 114. ASTRAZENECA PLC.: OPERATING SEGMENTS
  • TABLE 115. ASTRAZENECA PLC.: PRODUCT PORTFOLIO
  • TABLE 116. ASTRAZENECA PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET
  • FIGURE 3. SEGMENTATION CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET
  • FIGURE 11. CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SEGMENTATION, BY BY DRUG TYPE
  • FIGURE 12. CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET FOR CHEMOTHERAPY DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET FOR TARGETED THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SEGMENTATION, BY BY ROUTE OF ADMINISTRATION
  • FIGURE 16. CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET FOR ORAL DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET FOR INTRAVENOUS DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 20. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 21. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 22. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 23. COMPETITIVE DASHBOARD
  • FIGURE 24. COMPETITIVE HEATMAP: CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET
  • FIGURE 25. Top player positioning, 2022
  • FIGURE 26. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 27. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 28. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 29. BIOGEN IDEC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 30. BIOGEN IDEC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 31. BIOGEN IDEC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 32. GENENTECH INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 33. GENENTECH INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 34. GENENTECH INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 35. F. HOFFMANN-LA ROCHE AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. GENZYME CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. GENZYME CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. GENZYME CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. CELGENE CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. CELGENE CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. CELGENE CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. GENMAB A/S: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. GENMAB A/S: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. GENMAB A/S: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. ASTRAZENECA PLC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. ASTRAZENECA PLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. ASTRAZENECA PLC.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Chronic Lymphocytic Leukemia Therapeutics Market

Start reading.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers